MedTrace Logo

Assessment of Vivity With French Clinical Data Related to the Toric Model Study

NCT05416177 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2022-08-25

No results posted yet for this study

Summary

Presbyopia-correcting implant (PC-IOL): AcrySof IQ Vivity (Alcon) has been evaluated in 2 large pivotal trials (US and OUS trials). These tests showed that this PC-IOL restored intermediate visual acuity (IVA) and near visual acuity (NV A) superior to that of the reference monofocal AcrySof implant. In these tests, it was demonstrated that distance visual acuity (DVA) was non-inferior. However, the intermediate visual acuity for this implant in its toric version has not been evaluated.

Conditions

  • Cataract

Sponsors & Collaborators

  • Versailles Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2023-04-01
Completion
2023-07-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05416177 on ClinicalTrials.gov